Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.50 Consensus PT from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $17.00.

ATEC has been the subject of a number of recent research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 30th. Needham & Company LLC reduced their target price on shares of Alphatec from $23.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, August 22nd. Lake Street Capital decreased their target price on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Thursday, August 1st. Finally, Stifel Nicolaus reduced their price objective on Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, August 1st.

Insider Buying and Selling

In related news, Director David M. Demski purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were purchased at an average price of $5.67 per share, with a total value of $283,500.00. Following the purchase, the director now owns 288,441 shares of the company’s stock, valued at $1,635,460.47. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 22.80% of the company’s stock.

Institutional Trading of Alphatec

Several large investors have recently added to or reduced their stakes in ATEC. Van ECK Associates Corp lifted its position in shares of Alphatec by 11.8% in the second quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock worth $128,000 after purchasing an additional 1,300 shares in the last quarter. ProShare Advisors LLC lifted its position in Alphatec by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 16,572 shares of the medical technology company’s stock worth $229,000 after buying an additional 1,304 shares in the last quarter. Bayesian Capital Management LP boosted its stake in shares of Alphatec by 5.6% during the 1st quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company’s stock valued at $372,000 after buying an additional 1,442 shares during the period. Cetera Advisors LLC grew its holdings in shares of Alphatec by 15.6% during the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock valued at $175,000 after acquiring an additional 1,720 shares in the last quarter. Finally, Comerica Bank increased its stake in shares of Alphatec by 64.8% in the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after acquiring an additional 2,534 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Stock Down 0.7 %

Shares of Alphatec stock opened at $5.67 on Tuesday. Alphatec has a 1-year low of $4.88 and a 1-year high of $17.34. The business has a 50-day moving average of $5.85 and a 200-day moving average of $9.16. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.21. The company has a market capitalization of $793.14 million, a PE ratio of -3.81 and a beta of 1.39.

Alphatec (NASDAQ:ATEC) last released its earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.03). Alphatec had a negative return on equity of 816.57% and a negative net margin of 33.48%. The company had revenue of $145.57 million during the quarter, compared to the consensus estimate of $144.55 million. During the same period in the previous year, the firm posted ($0.43) EPS. Alphatec’s revenue for the quarter was up 24.5% on a year-over-year basis. As a group, equities analysts forecast that Alphatec will post -1.08 EPS for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.